U.S. markets closed

Perrigo Company plc (0Y5E.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
75.69+21.80 (+40.45%)
At close: 11:52AM BST
Sign in to post a message.
  • T
    Good day, my ACOR friends
  • G
    When will the Irish judge rule for heaven's sake?
  • S
    Sammy Z
    $EVOK great movement PRGO, watch out they may buyout Evoke Pharma: Monday CEO Gonyer will finally have the opportunity to update/promote Gimoti. Realistically it will be the first time since FDA approval in June, Evoke’s CEO will be able to tell Gimoti’s successful story moving forward. CEO will have the attention of thousands of wealthy institutional/hedge funds/public investors, from all over the world.


    H.C. Wainwright 22nd Annual Global Investment Conference taking place September 14 – September 16, 2020.

    EVOKE’S Corporate Presentation
    Monday, September 14, 2020
    2:00 pm ET (presentation)

    Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Last year world wide over a $10 billion was spent on Diabetic Gastro relief.
  • S
    Sammy Z
    EVOK Evoke Pharma Why Perrigo is looking to buyout Evoke Pharma’s newly approved Diabetic Gimoti relief.

    1. First approved drug Gimoti for Diabetic Gastro since 1989. Will replace the Needle/ pill form of the same drug. In the USA a lone over 3/4 million prescriptions a year.

    2. Last year 10 billion world wide sales in Diabetic Gastro Market, growing daily.

    3. Drug has been used for Migraines, cancer and post operation surgery.

    4. EVOKE can black label Gimoti, sell to multiple mentioned markets that produce billions of sales every year.

    5. 10 year patent in USA, 12 years outside the USA. Curently there is no compition only approved drug.

    6. The potential sales with attacking all market suffers, could easily exceed 500 million. All markets mentioned are growing daily.

    7. Company has 24M shares in circulation. roughly 22M in reserve.

    8. CEO Gonyer has sold every FDA approved drug he has been involved with.

    This is a great investment at this very low price. Monday Evoke has a world wide investors presentation at the H.C. Wainwright investment conference.
  • S
    Sammy Z
    $VXL.V VXLLF Vaxil Bio will partner with big Pharma very soon.
    NESS-ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that it has achieved positive results for the in vivo (animal) immunogenicity study which commenced on July 14, 2020.

    The experiments, performed at the Medical Research. These results further confirm the potential in the design of Vaxil’s COVID-19 vaccine candidate and provide additional evidence that it generates the anticipated immune response. A total of three injections were inoculated in two mouse strains to better simulate the human immune environment for which CorVax™ was specifically designed. Both mouse strains exhibited a humoral response, developing antibodies as early as 10 days after last injection. Both strains also displayed activated T cells against the signal peptides.
  • Y
    Yahoo Finance Insights
    Perrigo is down 4.94% to 48.35
  • p
    I started following "awesomestokcalerts" (Gooogle it - off course without any space or dash in between the words) and their notifications are better than anyone else.
  • W
    glad I sold PRGO at $190/sh a couple years back....I thought they should have accepted the buyout offer
  • s
    Wouldn’t the prudent response be to move their headquarters out of Ireland and into the US - though spiteful, with the recent cut to US corporate tax it would probably a neutral move with respect to future taxes.
  • D
    Am I the only one interested in the stock ?? this conversation page is dead. Has everyone alreaedy lost faith in perrigo . no hope ? I still own quite a lot of shares and believe that new management can really rebuild this company and eventually someone will want to buy it. Companies like Mylan must be considering a second offer. probably not as high as the original but somewhere around 110 120.
  • P
    Any facts to support claims that Amazon will contract with Perrigo to make medical products for Amazon to sell?
    I got a broker calling me with a buy recommendation for PRGO due to pending business alliance between Amazon and Perrigo.
    Please advise.
  • V
    everyone sold tesaro and it tripled. this is hedge fund redemption related, believe in the company then buy it. otherwise good bye
  • D
    Didn't Perrigo trade near 200 a couple of years ago and was a takeover candidate? What the h... happened?
  • A
    Well, new management has started delivering.
  • D
    I believe we can expect a small pop in the next few days. Stay tuned
  • J
    great new CEO
  • h
    never overestimate your power to change others. http://dataunion.tistory.com/8904 A person who does not try, cannot succeed.
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.7 In ot..
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.7 In ot..
  • D
    less than 2% div not enough to buy in this market. unemployment numbers may get worse.
  • e
    Perrigo is very well positioned to take advantage of covid economic conditions- they sell cheap good quality medicine , with strong distribution of products across many countries , just what shrinking houshold and national budgets need .
  • t
    Scientists at the University of Oxford said on Tuesday that they have identified what they called the first drug proven to reduce coronavirus-related deaths, after a 6,000-patient trial of the drug in Britain showed that a low-cost steroid could reduce deaths significantly for hospitalized patients.

    The steroid, dexamethasone, reduced deaths by a third in patients receiving ventilation, and by a fifth in patients receiving only oxygen treatment, the scientists said. They found no benefit from the drug in patients who did not need respiratory support